Suggestions
Manijeh Goldberg, PhD
CEO Privo Technologies, Harvard Medical School, MIT
Manijeh Goldberg, Ph.D., is a prominent figure in the biomedical field, currently serving as a Scientific Reviewer at the National Cancer Institute (NCI). She has an extensive background in cancer research and innovative treatment technologies, particularly focusing on targeted cancer therapies.
Educational Background
Dr. Goldberg holds multiple advanced degrees:
- Ph.D. in Biomedical Engineering from the University of Massachusetts
- M.S. in Health Sciences and Technology from Harvard Medical School
- MBA from MIT Sloan School of Management
- M.S. in Computer Science and Mathematics from the University of Massachusetts, Lowell.12
Professional Experience
Dr. Goldberg is also the Founder and CEO of Privo Technologies, a company that specializes in developing nanoparticle-based drug delivery systems aimed at treating various cancers, including oral and head and neck cancers. Under her leadership, Privo has made significant advancements, including a novel delivery system that has shown promising results in clinical trials, with an overall response rate of 87% among patients treated for oral cavity cancer.24
Her work has been recognized with several awards, including the Tibbetts Award at the U.S. White House for her contributions to the Small Business Innovation Research program.2 Dr. Goldberg has also been involved in mentoring young scientists and promoting women in science.2
Research Contributions
Dr. Goldberg's research primarily focuses on:
- Nano-engineered drug delivery systems: These systems allow for targeted delivery of anti-cancer agents directly to tumor sites, minimizing systemic toxicity and improving treatment efficacy.23
- Innovative therapies for solid tumors: Her team is working on treatments that could revolutionize how solid tumors are managed post-surgery by eliminating residual cancer cells.4
Through her role at the NCI and her leadership at Privo Technologies, Dr. Goldberg continues to contribute significantly to cancer research and treatment innovation, aiming to improve patient outcomes and advance the field of oncology.